Showing 4091-4100 of 8583 results for "".
- Sirnaomics Gets FDA Go Ahead to Move STP705 Into Late-Stage Clinical Development for isSCChttps://practicaldermatology.com/news/sirnaomics-gets-fda-go-ahead-to-move-stp705-into-late-stage-clinical-development-for-isscc/2461788/Sirnaomics Ltd.’s STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) is moving into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results. These results were shared with the U.S. Food and Drug Administration (FDA) in an En
- FDA Nod for Avita Medical’s RECELL for Skin Repigmentation in Vitiligo Patientshttps://practicaldermatology.com/news/fda-nod-for-avita-medicals-recell-for-skin-repigmentation-in-vitiligo-patients/2461787/The U.S. Food and Drug Administration (FDA) has approved AVITA Medical, Inc.’s application for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic d
- DFD-29 Shows No Major impact on Healthy Microbial Flora in Rosaceahttps://practicaldermatology.com/news/dfd-29-shows-no-major-impact-on-healthy-microbial-flora-in-rosacea/2461785/DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) doesn’t disrupt the microbial floral in healthy adults with papulopustular rosacea, according to data from a Phase 1 clinical trial. DFD-29 is being developed for the treatment of papulopustular ros
- Merz Aesthetics News: Xeomin Scores in Phase 3 Studies of Upper Facial Lineshttps://practicaldermatology.com/news/merz-aesthetics-news-xeomin-performs-well-in-phase-3-studies-of-upper-facial-lines/2461781/Two pivotal phase 3 clinical studies demonstrated the efficacy and safety of Xeomin (incobotulinumtoxinA) in the simultaneous treatment of horizontal forehead lines, glabellar frown lines, and lateral canthal lines, according to Merz Aesthetics. Merz Aesthetics will submit these data as
- EAACI News: Novel Antibody May Help Treat Melanomahttps://practicaldermatology.com/news/novel-antibody-may-help-treat-melanoma/2461775/A newly discovered antibody may benefit patients with melanoma who do not respond to current immunotherapies, according to a study presented at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI). Unlike
- Engineered Human Tissue May Help Study Mosquito Bites, Diseaseshttps://practicaldermatology.com/news/engineered-human-tissue-may-help-study-mosquito-bites-diseases/2461774/Researchers have created engineered human tissue to study mosquito bites and the diseases they transmit. The team led by College of Medicine biomedical researcher Bradley Jay Willenberg with Mollie Jewett (UCF Burnett School of Biomedical Sciences) and Andrew Dickerson (University of Te
- New RNA Monitoring Method May Allow for Early Diagnosis of AD in Infantshttps://practicaldermatology.com/news/new-rna-monitoring-method-may-allow-for-early-diagnosis-of-ad-in-infants/2461771/A novel monitoring method that enables human skin transcriptome analysis of the mRNA in sebum) collected from the skin using a simple oil-blotting film may help diagnose atopic dermatitis earlier than is currently possible. According to a newstudy
- Can Softening Stem Cells Coax Hair Growth in Aging Hair? Maybehttps://practicaldermatology.com/news/can-softening-stem-cells-coax-hair-growth-in-aging-hair/2461761/Hair follicle stem cells get stiff with age, making it harder for them to grow hair, but if the hair follicle’s stem cells are softened, they are more likely to produce hair, new research suggests. In a study in mice
- Memory Killer Cells May Boost Survival in Melanomahttps://practicaldermatology.com/news/memory-killer-cells-may-boost-survival-in-melanoma/2461758/High levels of memory killer cells in cancer tissue may boost survival in people with melanoma, a new study shows. Certain immune T cells called tissue-resident memory cells are formed locally in the skin and other tissue and protect against infections that they have encountered before.
- Scientists Identify Genomic Cause and Potential Treatment for Disabling Pansclerotic Morpheahttps://practicaldermatology.com/news/scientists-identify-genomic-cause-and-potential-treatment-for-disabling-pansclerotic-morphea/2461756/Researchers have identified genomic variants that cause disabling pansclerotic morphea and have found a potential treatment. People with the disorder have an overactive version of a protein called STAT4, which regulates inflammation and wound healing. The work also identified a drug tha